SEC
|
Berkley Neil Lindsay
|
Principal Financial Officer
|
|
-16K
|
$2.50
|
-$39.61K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-24K
|
$2.50
|
-$59.10K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-52K
|
$2.50
|
-$128.91K
|
|
SEC
|
Wong-Sarad Grace
|
Principal Accounting Officer
|
|
-5.9K
|
$2.50
|
-$14.78K
|
|
SEC
|
Hammond Paula
|
N/A
|
|
-14K
|
$2.36
|
-$33.04K
|
|
SEC
|
Yaffe Kristine
|
N/A
|
|
-1K
|
$1.44
|
-$1.44K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-16K
|
$1.34
|
-$22.09K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-24K
|
$1.34
|
-$32.01K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-52K
|
$1.34
|
-$69.80K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-18K
|
$1.47
|
-$26.59K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-29K
|
$1.47
|
-$42.74K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-16K
|
$1.47
|
-$23.97K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-40K
|
$1.47
|
-$59.29K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-16K
|
$2.52
|
-$41.55K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-27K
|
$2.52
|
-$66.78K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-15K
|
$2.52
|
-$37.53K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-52K
|
$2.52
|
-$131.47K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-7.3K
|
$4.88
|
-$35.61K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-14K
|
$4.88
|
-$67.96K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-8.5K
|
$4.88
|
-$41.37K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-26K
|
$4.88
|
-$129.32K
|
|
SEC
|
SCHELLER RICHARD H
|
N/A
|
|
-44K
|
$5.16
|
-$228.33K
|
|
SEC
|
Hammond Paula
|
N/A
|
|
-11K
|
$5.06
|
-$53.13K
|
|
SEC
|
Yaffe Kristine
|
N/A
|
|
-5K
|
$5.06
|
-$25.30K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-6.9K
|
$4.80
|
-$33.22K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-13K
|
$4.80
|
-$63.39K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-8K
|
$4.80
|
-$38.59K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-25K
|
$4.80
|
-$120.65K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-5.7K
|
$6.92
|
-$39.55K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-10K
|
$6.92
|
-$70.37K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-6K
|
$6.92
|
-$41.53K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-19K
|
$6.92
|
-$130.35K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-4.6K
|
$5.56
|
-$25.43K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-13K
|
$5.56
|
-$69.61K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-5K
|
$5.56
|
-$27.99K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-24K
|
$5.56
|
-$132.50K
|
|
SEC
|
MCGUIRE TERRANCE
|
N/A
|
|
-500K
|
$6.00
|
-$3.00M
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-1.1K
|
$5.19
|
-$5.78K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-6.2K
|
$5.19
|
-$32.25K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-2.8K
|
$5.19
|
-$14.38K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-5.6K
|
$5.19
|
-$29.31K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-1.1K
|
$6.90
|
-$7.25K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-4.1K
|
$6.90
|
-$28.23K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-2.6K
|
$6.90
|
-$18.06K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-5.3K
|
$6.90
|
-$36.26K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-15K
|
$6.22
|
-$94.46K
|
|
SEC
|
GRASSO MARC
|
Chief Financial Officer
|
|
-1.3K
|
$8.32
|
-$10.74K
|
|
SEC
|
Kenkare-Mitra Sara
|
President and Head of R&D
|
|
-10K
|
$8.32
|
-$84.23K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-5.4K
|
$8.47
|
-$45.59K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-5.8K
|
$8.32
|
-$48.66K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-176
|
$10.62
|
-$1.87K
|
|
SEC
|
Romano Gary
|
Chief Medical Officer
|
|
-2.2K
|
$10.62
|
-$23.12K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-354
|
$8.71
|
-$3.08K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-287
|
$15.57
|
-$4.47K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-250
|
$20.09
|
-$5.02K
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-110K
|
$25.00
|
-$2.75M
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-200K
|
$25.00
|
-$5.00M
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-200K
|
$25.00
|
-$5.00M
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-110K
|
$25.31
|
-$2.77M
|
|
SEC
|
Rosenthal Arnon
|
Chief Executive Officer
|
|
-200K
|
$25.96
|
-$5.19M
|
|
SEC
|
Yaffe Kristine
|
N/A
|
|
+2K
|
$18.10
|
+$36.20K
|
|
SEC
|
SCHELLER RICHARD H
|
N/A
|
|
-10K
|
$19.91
|
-$198.72K
|
|
SEC
|
Yu Calvin
|
Vice President, Finance
|
|
-50K
|
$25.72
|
-$1.29M
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-39K
|
$24.65
|
-$971.21K
|
|
SEC
|
Yu Calvin
|
Vice President, Finance
|
|
-1.8K
|
$17.77
|
-$32.77K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$22.96
|
-$229.60K
|
|
SEC
|
MCGUIRE TERRANCE
|
N/A
|
|
-4.4K
|
$31.54
|
-$138.05K
|
|
SEC
|
PVP VI (AIV) Feeder Corp. Holding Partnership, L.P.
|
N/A
|
|
-4.4K
|
$31.54
|
-$138.05K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$29.61
|
-$296.10K
|
|
SEC
|
Yu Calvin
|
Vice President, Finance
|
|
-1.3K
|
$31.26
|
-$41.98K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-15K
|
$27.00
|
-$405.00K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$27.00
|
-$270.00K
|
|
SEC
|
OrbiMed Capital GP IV LLC
|
N/A
|
|
-85K
|
$23.53
|
-$2.01M
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$22.27
|
-$222.70K
|
|
SEC
|
OrbiMed Capital GP IV LLC
|
N/A
|
|
-380K
|
$23.74
|
-$9.02M
|
|
SEC
|
OrbiMed Capital GP IV LLC
|
N/A
|
|
-250K
|
$24.50
|
-$6.13M
|
|
SEC
|
OrbiMed Capital GP IV LLC
|
N/A
|
|
-139K
|
$24.70
|
-$3.42M
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$22.93
|
-$229.30K
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
-1.9M
|
$26.00
|
-$48.73M
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-15K
|
$29.56
|
-$443.40K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$29.54
|
-$295.40K
|
|
SEC
|
Oney Sabah
|
Chief Business Officer
|
|
-20K
|
$35.03
|
-$697.10K
|
|
SEC
|
Yu Calvin
|
Vice President, Finance
|
|
-15K
|
$27.07
|
-$395.44K
|
|
SEC
|
Oney Sabah
|
Chief Business Officer
|
|
-100
|
$19.13
|
-$1.91K
|
|
SEC
|
SCHELLER RICHARD H
|
N/A
|
|
-10K
|
$29.67
|
-$296.70K
|
|
SEC
|
Yu Calvin
|
Vice President, Finance
|
|
-50K
|
$26.20
|
-$1.31M
|
|
SEC
|
Wehner David M.
|
N/A
|
|
+20K
|
$25.00
|
+$500.00K
|
|
SEC
|
Oney Sabah
|
Chief Business Officer
|
|
-17K
|
$25.07
|
-$417.84K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-6K
|
$24.32
|
-$145.92K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-15K
|
$22.01
|
-$330.15K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$18.67
|
-$186.70K
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
-380K
|
$19.50
|
-$7.41M
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
-519K
|
$19.66
|
-$10.21M
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
-954K
|
$18.52
|
-$17.67M
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$20.03
|
-$200.30K
|
|
SEC
|
Yu Calvin
|
Vice President, Finance
|
|
-1.3K
|
$18.31
|
-$24.08K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-7.5K
|
$15.92
|
-$119.40K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$15.93
|
-$159.30K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$14.68
|
-$146.80K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$19.08
|
-$190.80K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-2K
|
$16.00
|
-$32.00K
|
|
SEC
|
King Robert
|
Chief Development Officer
|
|
-7.5K
|
$15.00
|
-$112.50K
|
|
SEC
|
Paul Robert
|
Chief Medical Officer
|
|
-10K
|
$14.19
|
-$141.90K
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
-650K
|
$17.90
|
-$11.64M
|
|
SEC
|
GORDON CARL L
|
N/A
|
|
+13M
|
$19.00
|
+$248.79M
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
+13M
|
$19.00
|
+$248.79M
|
|